Publication Name	World Journal of Gastroenterology
Manuscript ID	5060
Country	China

Received	2013-08-12 15:21
Peer-Review Started
To Make the First Decision
Return for Revision
Revised
Second Decision	2013-08-13 12:16
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2013-08-13 13:53
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2013-10-12 19:47
Publish the Manuscript Online	2013-11-08 14:06

ISSN	1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Meta-Analysis
Article Title	Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis
Manuscript Source	Invited Manuscript
All Author List	Xiao-Guang Ye and Qi-Min Su
Funding Agency and Grant Number	Funding Agency Grant Number Chinese Foundation for Hepatitis Prevention and Control, Fund of “Guanghui” 2012208
Corresponding Author	Dr. Xiao-Guang Ye, Department of Infectious Diseases, the Second Affiliated Hospital of Guangzhou Medical University, Guangzhou 510260, Guangdong Province, China. yexiaoguang@126.com
Key Words	Hepatitis B; Decompensated cirrhosis; Entecavir; Lamivudine; Randomized controlled trial; Meta-analysis.
Core Tip	This meta-analysis was conducted to compare the effects of entecavir (ETV) and lamivudine (LAM) in the treatment of hepatitis B associated decompensated cirrhosis. The results suggested that ETV and LAM significantly improved liver function and reduced mortality. Both drugs produced similar serological responses, and were safe and well tolerated. However, LAM had higher drug-resistance and is therefore unsuitable for the long-term treatment of patients with hepatitis B decompensated cirrhosis. ETV can be used as the first-line drug for long-term treatment of patients with hepatitis B decompensated cirrhosis as it has stronger anti-viral activity and extremely low drug-resistance.
Publish Date	2013-11-08 14:06
Citation	Ye XG, Su QM. Effects of entecavir and lamivudine for hepatitis B decompensated cirrhosis: Meta-analysis. World J Gastroenterol 2013; 19(39): 6665-6678
URL	http://www.wjgnet.com/1007-9327/full/v19/i39/6665.htm
DOI	http://dx.doi.org/10.3748/wjg.v19.i39.6665

Full Article (PDF)	WJG-19-6665.pdf
Manuscript File	5060-Review.doc
Answering Reviewers	5060-Answering reviewers.pdf
Copyright License Agreement	5060-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate	5060-Language certificate.doc
Peer-review Report	5060-Peer review(s).pdf
Scientific Editor Work List	5060-Scientific editor work list.doc